Selenase Action on the Energy Metabolism and Prooxidant-Antioxidant System Data in the Rats Organs with Toxic Hepatitis

Pogotova G. A., Gorchakova N. A., Belenichev I. F., Chekman I. S.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Introduction. Selenase is indispensable important as life element, which is actively involved in the functioning of some biological systems. Selenium is part of glutathione peroxidase (associated with the protein form as selenocysteine aminoacids), the enzyme that destroying hydroxyperoxides and thus protects the membrane lipids, and other cells components against oxidative damage by free radicals. Modernly it is proved the role of selenium in the development of alimentary diseases, metabolic syndrome, liver diseases and other critical status. In connection that the development of digestive tract, cardiovascular, nervous and other systems diseases, and critical status accompanied by balance violation between the lipids peroxidation system and antioxidant defense system, it is important to look for the new antioxidant agents. It is proved the positive effect of selenase drug in the treatment of pancreatitis and critical status. Taking into attention that in the liver diseases there are cardiovascular and nervous system damages it is important hepatoprotectors search possessing the total organoprotective action. Aim of the investigation. Determination of selenase action on the energy metabolism and prooxidant­antioxidant system data in the rats organs with toxic hepatitis. Objects and methods. Experimental studies were carried out on 21 nonlinear white rats­males body weight, 170­190 g. The experiments with rats was conducted according to Methodical recommendations of the SCE of the Ministry of health of Ukraine. For modeling toxic hepatitis it was used dichloroethane that administered orally to rats through the metal atraumatic probe at a dose of 500 ml/kg in a 50 % solution in sunflower oil 1 time a day for 4 days. On the 5th day of the experiment, the introduction of a toxic agent was stopped, and within 10 days the rats were divided into 3 groups of 7 animals: group 1 – the intact animals, group 2 – the animals with toxic hepatitis, group 3 – the animals with toxic hepatitis and selenase administration. Selenase organoprotective activity has bean studied on dichlorethane hepatitis experimental models in course intragastric administration in the dose of 50 mkg/ kg within 20 days after pathology modeling. Research results and their discussion. It is established that the modeling of chronic toxic hepatitis led to the destruction of the major target organs: liver, myocardium and brain of experimental animals. So, in cytosole of liver, heart and brain homogenates of untreated animals in was shown the significant markers elevations markers of oxidative modification of proteins (OMP) – AFG and KFG in the phone of antioxidant system oppression (SOD activity, GPR and reduced glutathione content reduction). It is established that selenase after modeling dichlorethane hepatitis normalizes the antioxidant system (SOD, GPO, reduced glutathione) and oxidative modification of proteins (AFG, KFG) in liver, myocardium, brain tissue of rats. Selenase normalizes the energy metabolism of the rats liver and myocardium (ATP, pyruvate, malate, lactate), does not effect on the energy metabolism data in the brain tissue of animals. Conclusion. Selenase after intragastric administration in dichlorethane hepatitis normalizes antioxidant system, oxidative modification of proteins in in liver, myocardium, brain tissue of rats and energy metabolism of the liver and myocardium.

Selenase, toxic hepatitis, energy metabolism, prooxidant­antioxidant system

• Вдовиченко В. І. поширеність неалкогольної жирової хвороби печінки серед померлих, які страждали на цукровий діабет 2 типу / В. І. Вдовиченко, Х. б. аксентійчук // сучасна гастроентерологія. – 2013. – т. 69, № 1. – с. 41–46
• громова о. а. селен – впечатляющие итоги и перспективы применения / о. а. громова, н. В. гоголева // Мед. неотл. состояний. – 2010. – т. 31, № 6. – с. 124–128.
• заремба Є. Х. Цитопротекторна терапія серцево­судинних захворювань / Є. Х. заремба, В. М. карпляк // львів. мед. часопис. – 2011. – том 17, № 1. – с. 106–111.
• камышников В. с. клинико­лабораторная диагностика заболеваний печени / В. с. камышников. – М.: Медпресс­ин­ форм, 2013. – 96 с.
• павлова н. о. исследование гепатопротекторного действия фитоантиоксидантов / о. н. павлова, е. а. грибанова, н. н. Желонкин [и др.] // известия самарского научного центра российской академии наук. – 2010. – т. 12, № 1. – с. 2088–2090.
• стефанов а. В. доклинические исследования лекарственных средств / а. В. стефанов. – киев : авиценна, 2002. – 568 с.
• усенко л. В. опыт применения селеназы в комплексе интенсивной терапии при критических состояниях / л. В. усенко, Ю. Ю. кобеляцкий, н. Ф. Мосенцев, и. а. йовенко // Медицина неотложных состояний. – 2011. – № 7­8. – с. 147–151.
• Фадеенко г. д. селеносодержащие препараты в лечении больных хроническим панкреатитом / г. д. Фадеенко, к. Ю. дубров // сучасна гастроентерологія. – 2010. – № 5. – с. 69–75.
• чекман и. с. доклиническое изучение специфической активности потенциальных нейропротективных препаратов / и. с. чекман, Ю. и. губский, и. Ф. беленичев [и др.]. – киев, 2010. – 81 с.
• Bozzetti F. The ESPEN clinical practice guidelines on parenteral nutrition: present status and perspectives for future research / F. Bozzetti, A. Forbes // Clin. Nutr. – 2009. – № 28. – р. 359–364.
• Collier B. R. Effects of trace element supplementation on the inflammatory response in a rabbit model of major trauma / B. R. сollier, A. Giladi, L. A. Dosset // J. of Trace Elements in Medicine and Biology. – 2010. – Vol. 24, № 1. – P. 36–41.
• Janbakhsh A. Effect of selenium on immune response against hepatitis B vaccine with accelerated method in insulin­ dependent diabetes mellitus patients / A. Janbakhsh, F. Mansouri, S. Vaziri [et al.] // Caspian J. Intern. Med. – 2013. – Vol. 4, № 1. – р. 603–606.
• Khan M. S., Dilawar S., Ali I., Rauf N. The possible role of selenium concentration in hepatitis B and C patients / M. S. Khan, S. Dilawar, I. Ali, N. Rauf // Saudi J. Gastroenterol. – 2012. – Vol. 18, № 2. – р. 106–110.
• Pinzani M. Update on the pathophysiology of liver fibrosi / M. Pinzani, J. Macias­Barragan // Expert. Rev. Gastroenterol. Hepatol. – 2010. – № 4. – р. 459–472.
• Rauf N. Serum selenium concentration in liver cirrhotic patients suffering from hepatitis B and C in Pakistan / Rauf N., Tahir S. S., Dilawar S. [et al.] // Biol. Trace Elem. Res. – 2012. – Vol. 145, № 2. – р. 144–150.

«Bulletin of problems biology and medicine» Issue 3 part 2 (111), 2014 year, 216-220 pages, index UDK 615. 272. 4+615. 244+547. 972.